

March 14, 2025

The National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051. **The BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.

Scrip Code: STAR

Scrip Code: 532531

Dear Madam/ Sir,

Ref: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)

Sub: Acquisition of 100% stake in Amexel Pte. Ltd., Singapore

We wish to inform you that Strides Pharma Global Pte. Limited ("SPG"), a step-down wholly-owned subsidiary of the Company in Singapore, proposes to create a platform that shall foster introductions, collaborations, procurement and business engagement between pharmaceutical manufacturers and suppliers of India, China, and other Southeast-Asian countries.

In this regard, it is proposed to acquire 100% stake in Amexel Pte. Ltd., Singapore, which will be utilized as the entity for the above business platform.

Disclosure under Regulation 30 of SEBI Listing Regulations for the said acquisition is enclosed for your information and records.

This is for your kind information and record purpose.

Thanks & Regards, For **Strides Pharma Science Limited**,

Manjula Ramamurthy Company Secretary ICSI Membership No. A30515



Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015

Acquisition of 100% stake in Amexel Pte. Ltd., Singapore

#	Particulars
a)	Name of the Target entity, details in brief such as size, turnover etc.
	Strides Pharma Global Pte. Limited (SPG), a step-down whollyowned Subsidiary of the Company in Singapore, proposes to create a platform that shall foster introductions, collaborations, procurement and business engagement between pharmaceutical manufacturers and suppliers of India, China, and other Southeast Asian countries.
	In this regard, it is proposed to acquire 100% stake in Amexel Pte. Ltd., Singapore (Amexel), which will be utilized as the entity for the above business platform.
	Amexel is a company incorporated under the laws of Singapore on March 22, 2023 and has its Registered Office at 36 Robinson Road, #13-06 City House, Singapore 068877.
	Amexel is yet to commence its operations. Financial parameters of Amexel for the period ended December 31, 2023 is as under:
	 Turnover: Nil and Profit/ Loss and Networth: Negligible
	SPG has entered into a Share Purchase Agreement to acquire 100% stake in Amexel for a nominal consideration of USD 10.
	Amexel, as WOS of SPG, shall focus on:
	• in-licensing, technology transfers, and the procurement of technical and manufacturing expertise for the production of pharmaceutical products at Strides' manufacturing facilities (or those of its affiliates) as well as other manufacturers in India.
	• identifying qualified and approved suppliers, sourcing partners, and providers of APIs, Raw Materials and Packaging materials.
	• building partnerships with distributors, commercial partners, and customers to support the supply, distribution, and commercialization of products across various territories.
	Amexel aims to generate revenue through facilitation services and a profit-sharing model linked to the commercialization of products.

Strides Pharma Science Limited



b)	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired?
	If yes, nature of interest and details thereof and whether the same is done at "arms length"
	Proposed transaction shall fall within the purview of related party transactions as Amexel is being acquired from a director of a Subsidiary. However, the said transaction is at arms' length basis.
	Promoter/ Promoter group of Strides Pharma Science Limited does not have any interest in the proposed transaction.
c)	Industry to which the entity being acquired belongs
	Pharmaceuticals
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)
	Refer clause (a) above.
e)	Brief details of any governmental or regulatory approvals required for the acquisition
	None
f)	Indicative time period for completion of the acquisition
	By March 31, 2025
g)	Consideration – whether cash consideration or share swap and details of the same; & Cost of acquisition and/ or the price at which the shares are acquired
	For a nominal cash consideration of USD 10
h)	Percentage of shareholding/ control acquired and/ or number of shares acquired
	100% equity stake of Amexel
i)	Brief background about the entity acquired in terms of products/ line of business acquired, date of incorporation, history of last 3 years turnover, Country in which the acquired entity has presence
	Refer clause (a) above.

Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India Tel: +91-80-6784 0000 Fax: +91 80 6784 0700 Regd Off: 'Cyber One', Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703, India Tel:+91-22-2789 2924/ 3199 corpcomm@strides.com; www.strides.com



(j)	Any other significant information
	None

Strides Pharma Science Limited CIN: L24230MH1990PLC057062 Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India Tel: +91-80-6784 0000 Fax: +91 80 6784 0700 Regd Off: 'Cyber One', Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703, India Tel:+91-22-2789 2924/ 3199 corpcomm@strides.com; www.strides.com